Skip to main content

Table 1 Baseline characteristics of the 1117 HIV-infected children included in the pWADA cohort, Abidjan, May-August 2012

From: Effect of cotrimoxazole prophylaxis on the incidence of malaria in HIV-infected children in 2012, in Abidjan, Côte d’Ivoire: a prospective cohort study

Characteristics (N = 1117) n (%)
Centre participants, n (%)
Cocody University Hospital 182 (16.3)
Yopougon University Hospital 344 (30.8)
CePReF 322 (28.8)
CIRBA 212 (19.0)
MTCT+ 57 (5.1)
Total site 1117 (100.0)
Age (years)
Median (IQR) 9 (6–12)
Sex, n (%)
Male 553 (49.5)
Female 564 (50.5)
HIV type, n (%)
1 1111 (99.4)
2 4 (0.4)
1 & 2 2 (0.2)
Last CD4 measurement available at the time of the visit
Percentage when age < 5 years n (%) 144 (13.0)
Median CD4 % (IQR) 29 (24–35)
CD4 > 35 %, n (%) 34 (23.6)
25 % ≤ CD4 ≤ 35 %, n (%) 66 (45.8)
CD4 < 25 %, n (%) 40 (27.8)
Missing, n (%) 4 (2.8)
Cell count when age ≥ 5 years n (%) 973 (87.0)
Median CD4 cells/mm3, (IQR) 781 (507–1084)
CD4 > 500 cells/mm3, n (%) 731 (75.1)
350 ≤ CD4 ≤ 500 cells/mm3, n (%) 102 (10.5)
CD4 < 350 cells/mm3, n (%) 140 (14.4)
Missing, n (%) 0 (0.0)
Treatment received at the time of the visit
On ART – On Cotrimoxazole 667 (59.7)
Off ART – On Cotrimoxazole 83 (7.4)
On ART – Off Cotrimoxazole 323 (29.0)
Off ART – Off Cotrimoxazole 35 (3.1)
On ART unknown for Cotrimoxazole 9 (0.8)
ART drugs regimen
2 NRTIa + 1 NNRTIb 842 (84.3)
2 NRTI + 1 PIc 144 (14.4)
3 NRTI 9 (0.9)
Missing 4 (0.4)
Median follow-up time on ART (year) (IQR) 2.2 (0.4-5.2)
Median follow-up time on Cotrimoxazole (year) (IQR) 3.4 (1.3-6.1)
  1. n: number; ART: antiretroviral therapy; NRTIa: Nucleoside Reverse Transcriptase Inhibitors. INNRTb: Non-Nucleoside Reverse Transcriptase Inhibitors. PIc: Protease Inhibitors